ReviewJournal of clinical medicine2025
Superior Vena Cava as an Arrhythmogenic Substrate in Atrial Fibrillation: Anatomical, Electrophysiological and Clinical Perspectives.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Empirical Superior Vena Cava Isolation Added to Pulmonary Vein Isolation in Atrial Fibrillation: A Systematic Review and Meta-Analysis.BMC cardiovascular disorders · 2026Pooled it
- Targeted Superior Vena Cava Isolation Combined With Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone Using Cryoballoon Ablation for Atrial Fibrillation.Clinical cardiology · 2026Article
- Successful isolation of arrhythmogenic superior vena cava via balloon-in-basket pulsed field ablation: Overcoming phrenic nerve proximity.HeartRhythm case reports · 2026Article
- A case of superior vena cava reentrant atrial tachycardia after pulmonary vein isolation with pentaspline pulsed field ablation.HeartRhythm case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catheter ablation is an established treatment method for atrial fibrillation. In most cases, the arrhythmia substrate is located within the pulmonary veins and their isolation has become the cornerstone of catheter ablation therapy. However, it is estimated that in 10-20% of patients, the trigger and/or sustaining factors for the arrhythmia are located outside the pulmonary veins. This is particularly relevant in patients with significant disease progression and persistent forms of AF, where these sites are likely responsible for treatment failure and arrhythmia recurrence. Identifying non-pulmonary vein triggers of AF and understanding their impact on disease progression is crucial but remains insufficiently explored. Gaining such insights offers hope for optimizing treatment strategies and improving outcomes for patients. The most commonly mentioned ectopic arrhythmogenic focus include the superior vena cava (SVC). Despite its clinical significance in arrhythmogenesis, the detailed electrophysiological properties of the SVC have received relatively limited research attention compared to other cardiac structures. Moreover, scientific papers that present extensive knowledge on SVC- from its embryology to the electrophysiology scarce. Therefore we would like to offer a comprehensive analysis of existing literature concerning SVC as an arrhythmogenic substrate for AF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.